Considering the marked negative effects of injury on TIMP1:MMP13 ratio in combination with the continued regional upregulation of MMP13 at 16 weeks in transected tendons, a prolonged therapeutic course with MMP inhibitors (possibly in combination with a controlled exercise program) may represent a possible avenue for future treatment of tendinopathy. Here, TIMP1 is linked to disease of the tendon.